Celcuity/$CELC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Celcuity
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Ticker
$CELC
Sector
Primary listing
Employees
87
Headquarters
Website
Celcuity Metrics
BasicAdvanced
$2.2B
-
-$3.45
0.68
-
Price and volume
Market cap
$2.2B
Beta
0.68
52-week high
$63.06
52-week low
$7.58
Average daily volume
1M
Financial strength
Current ratio
4.584
Quick ratio
4.216
Long term debt to equity
223.721
Total debt to equity
224.034
Interest coverage (TTM)
-11.27%
Profitability
EBITDA (TTM)
-146.486
Management effectiveness
Return on assets (TTM)
-38.50%
Return on equity (TTM)
-134.54%
Valuation
Price to book
46.07
Price to tangible book (TTM)
46.07
Price to free cash flow (TTM)
-18.781
Free cash flow yield (TTM)
-5.32%
Free cash flow per share (TTM)
-2.797
Growth
Earnings per share change (TTM)
28.56%
3-year earnings per share growth (CAGR)
18.83%
What the Analysts think about Celcuity
Analyst ratings (Buy, Hold, Sell) for Celcuity stock.
Bulls say / Bears say
Topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial showed the gedatolisib combination cut the risk of disease progression or death by 76% (HR 0.24), achieving a median progression-free survival of 9.3 months compared to 2.0 months for fulvestrant, representing unprecedented efficacy in HR+/HER2– advanced breast cancer.
The FDA has agreed to review the gedatolisib NDA through its Real-Time Oncology Review (RTOR) program, potentially speeding up the review process and supporting an earlier approval decision.
A financing round completed in Q2 2025 secured net proceeds of $286.5 million, giving the company a pro forma cash balance of $455 million—enough, management says, to fund operations through 2027 and support regulatory and commercial efforts.
AstraZeneca and Daiichi Sankyo’s Datroway antibody–drug conjugate has delivered significant improvements in overall survival and progression-free survival in late-stage breast cancer, potentially reducing the market potential for gedatolisib.
BioNTech and Duality Biologics’ precision therapy BNT323 showed strong progression-free survival outcomes in HER2-positive advanced breast cancer, highlighting increased competition that could limit gedatolisib’s adoption if it does not secure additional indications.
The PIK3CA-mutant arm of the Phase 3 VIKTORIA-1 trial is still enrolling, with topline results not expected until Q4 2025, creating ongoing execution risk and delaying potential commercial validation.
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
Celcuity Financial Performance
Revenues and expenses
Celcuity Earnings Performance
Company profitability
Celcuity News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Celcuity stock?
Celcuity (CELC) has a market cap of $2.2B as of October 17, 2025.
What is the P/E ratio for Celcuity stock?
The price to earnings (P/E) ratio for Celcuity (CELC) stock is 0 as of October 17, 2025.
Does Celcuity stock pay dividends?
No, Celcuity (CELC) stock does not pay dividends to its shareholders as of October 17, 2025.
When is the next Celcuity dividend payment date?
Celcuity (CELC) stock does not pay dividends to its shareholders.
What is the beta indicator for Celcuity?
Celcuity (CELC) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.